Optimum Investment Advisors’s Galectin Therapeutics GALT Stock Holding History

Optimum Investment Advisors’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-20	Closed	–	–	895
2019 Q4	$0	Hold	20	–	–	﹤0.01%	968
2019 Q3	$0	Hold	20	–	–	﹤0.01%	999
2019 Q2	$0	Hold	20	–	–	﹤0.01%	963
2019 Q1	$0	Hold	20	–	–	﹤0.01%	1011
2018 Q4	$0	Hold	20	–	–	﹤0.01%	980
2018 Q3	$0	Hold	20	–	–	﹤0.01%	1056
2018 Q2	$0	Hold	20	–	–	﹤0.01%	1069
2018 Q1	$0	Buy	+20	New	+$93	﹤0.01%	1015
2015 Q1	$4K	Hold	1,126	–	–	﹤0.01%	903
2014 Q4	$4K	Buy	1,126 +500	+80%	+$2.21K	﹤0.01%	929
2014 Q3	$3K	Hold	626	–	–	﹤0.01%	869
2014 Q2	$9K	Sell	626 -210	-25%	-$2.61K	﹤0.01%	788
2014 Q1	$13K	Buy	836 +96	+13%	+$1.37K	﹤0.01%	568
2013 Q4	$6K	Hold	740	–	–	﹤0.01%	649
2013 Q3	$7K	Buy	+740	New	+$4.99K	﹤0.01%	609

Other funds holding GALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Optimum Investment Advisors's GALT Position: Q1 2020 in Review

Optimum Investment Advisors sold out of Galectin Therapeutics (GALT) in Q1 2020, closing a stake of 20 shares.

Optimum Investment Advisors first reported a position in GALT in Q3 2013 and held it in 15 quarters. The position peaked at $13K in Q1 2014. 77 funds tracked by Wall St. Rank hold GALT as of Q1 2020.

Optimum Investment Advisors reported no remaining Galectin Therapeutics position as of Q1 2020 after selling out during the quarter.
Optimum Investment Advisors sold 20 Galectin Therapeutics shares in Q1 2020.
Optimum Investment Advisors first reported a position in Galectin Therapeutics in Q3 2013 and held it in 15 quarters.
Optimum Investment Advisors's Galectin Therapeutics position peaked at $13K in Q1 2014.
77 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2020.

Based on Optimum Investment Advisors's 13F filing for Q1 2020, filed 21 Apr 2020.